Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (482)	3/6/1999 9:48:00 PM
From: mike head	Read Replies (2) \| Respond to of 4974

Another of my mildly OT 'editorials'? Actually, pretty interesting stuff, IMO! Pax et Bonum, mch BALTIMORE, MD -- March 2, 1999 -- Nearly 90 percent of prostate cancers are linked to a previously unsuspected but common genetic process that could be reversible, Johns Hopkins researchers say. The process looks to be a fundamental one in cancer and appears in other common forms of the disease, like breast cancer. Unlike cancers due to mutations that make structural changes in a gene, such as the colon cancers that run in families, most prostate cancer may involve a process called gene switching, the researchers said. Switching occurs when certain members of a family of genes are switched on while others in the family shut down. "It's a process common during embryonic development," said molecular pathologist Shrihari Kadkol, M.D., Ph.D., one of the researchers in a study appearing today in Nature Medicine. "We believe this is the first time anyone's definitively linked gene switching within a family of genes, with cancer." "Most important is that someday, it's likely we can reverse switching with drugs," said molecular pathologist Gary Pasternack, M.D., Ph.D., who led the Hopkins research team. "This means one of the commonest cancers in men has the potential of being corrected without using typical gene therapy." In their work, the scientists used molecular probes to highlight and compare the gene activity in cancer patients' normal prostate tissue with that of their tumours. The investigators found clear evidence that a gene called pp32 was switched on in normal cells but generally switched off in cancer cells. Earlier studies by the team showed pp32 acts as a suppressor and keeps cells from turning malignant. Yet close relatives of the gene, to the researchers' surprise, act like pp32's genetic evil twins and encourage tumour growth. The pp32r1 and pp32r2 genes are present and turned on in perhaps 90 percent of the prostate cancers the team studied. "We first thought pp32 had just mutated but the types of differences between it and the variant genes told us this wasn't the case," Kadkol said. The researchers added switching could be a fundamental process in cancer and they've already linked it with common forms of breast cancer. "In the breast cancer patients we've examined we saw this same pp32 switching pattern," Kadkol explained. "If we can understand how the switching process works, what controls it we can potentially reverse it,” Pasternack added. "That's our next task." If their work goes smoothly, he adds, they could screen and find drugs for this purpose within two years. Then the candidate investigational drug would undergo the usual FDA-sponsored tests in people. "We also believe this work may have a role in diagnosis or in predicting disease outcome," Pasternack said. "Prostate specific antigen, the present common screen for prostate cancer, doesn't always tell the complete story or, particularly in older men, doesn't let us make a clear prognosis. This might help."

To: scaram(o)uche who wrote (482)	3/9/1999 11:40:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

I think that the PNU/CNTO news qualifies, as it shows the power that can be achieved, in short order, from establishing a top sales force (AGPH sold for $21. billion)...... 03/08/99 CNTO, sales force leverage, LMW heparin with PNU 03/05/99 garbage 03/04/99 AGPH, describes crystal structure for VEGFR2 kinase 03/03/99 garbage 03/02/99 INCY, using new chemistry from Amersham Pharmacia, flying 03/01/99 GLIA, finishes single-dose portion of phase I, GT-2331 03/01/99 GILD-NXTR merger 02/26/99 MEDI/Ixsys, MAb alliance, including anti-alpha-v beta-3 02/25/99 ONXX, Bayer select lead compound, ras pathway inhibitor